Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 103 of 1,261
  1. US 12054501

    Compositions and methods for inhibiting arginase activity

    Precision Pharmaceuticals, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  2. US 12054492

    Imidazole-containing inhibitors of ALK2 kinase

    BioCryst Pharmaceuticals, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  3. US 12053531

    Materials and methods for treatment of Duchenne Muscular Dystrophy

    Vertex Pharmaceuticals Incorporated · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  4. US 12053494

    Compositions comprising nanoparticles, method of making and uses thereof

    ORGANICELL REGENERATIVE MEDICINE, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  5. IT 202300001434

    PRODOTTO DI FERMENTAZIONE PER USO NEL TRATTAMENTO DI PATOLOGIE ASSOCIATE ALLA SINDROME METABOLICA E STEATOSI EPATICA.

    ALFASIGMA SPA [IT] · Granted Aug 1, 2024 · Expires Jul 27, 2044

    granted
  6. US 12049486

    PAC1 receptor agonists (MAXCAPs) and uses thereof

    The United States Government represented by the Department of Veterans Affairs · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  7. US 12048710

    Compositions and methods for modification of biomolecules

    The Regents of the University of California · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  8. US 12048687

    Methods of recruiting SDF-producing macrophages

    MedRegen, LLC · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  9. US 12048692

    Methods for treating chronic obstructive pulmonary disease

    Theravance Biopharma R&D IP, LLC · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  10. US 12048691

    High dosage tebipenem pivoxil tablet formulation

    SPERO THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  11. US 12050227

    Lipid nanodisc formation by acryloyl-based copolymers

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  12. US 12049644

    Platform for generating safe cell therapeutics

    The Regents of the University of California · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  13. US 12049487

    Universal chimeric antigen receptor T-cell preparation technique

    GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  14. US 12049479

    Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom

    Inovio Pharmaceuticals, Inc. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  15. US 12049471

    Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof

    NURIX THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  16. US 12048317

    Astaxanthin-containing condiment and a preparation method therefor

    South China University of Technology · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  17. US 12049520

    Bicyclic peptide ligands specific for CD137

    BicycleTx Limited · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  18. US 12049464

    Compounds for targeted degradation of BRD9

    C4 THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  19. US 12048747

    Substituted piperidine Degronimers for Target Protein degradation

    C4 THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  20. US 12048748

    Spirocyclic degronimers for target protein degradation

    C4 THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  21. US 12049457

    Highly purified pharmaceutical grade tasimelteon

    VANDA PHARMACEUTICALS INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  22. US 12049489

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  23. US 12049505

    Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  24. US 12049510

    Chimeric antigen receptor

    AUTOLUS LIMITED · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.